MedTrace Logo

Sugammadex v.s. Neostigmine/Glycopyrrolate

NCT06398899 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2025-09-12

No results posted yet for this study

Summary

The aim of study is to clarify the role of sugammadex in ENT surgery patients with a prior history of postoperative urinary retention, benign prostatic hypertrophy, or a history of prostate cancer, to prevent postoperative urinary retention. The main question it aims to answer are:

* Anticholinergic agent interferes the postoperative urination
* Sugammadex does not interfere postoperative urination Sugammadex can be recommended for these patients with high risk in postoperative urinary retention in the future.

Conditions

  • Head and Neck Surgery
  • Chronic Sinusitis
  • Chronic Otitis Media
  • Laryngeal Disease

Interventions

DRUG

Group S: sugammadex injection

Reversal agent: sugammadex

DRUG

Group N: neostigmine/glycopyrrolate

Reversal agent: glycopyrrolate and neostigmine

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • PEILIN LN · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-06-12
Completion
2025-08-12

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06398899 on ClinicalTrials.gov